Press release
Trypanosomiasis Therapeutics Pipeline Analysis 2018 | Sequella, Inc.
Trypanosomiasis is an infectious disease caused by the parasite of the genus Trypanosoma. African trypanosomiasis, or sleeping sickness, is caused by Trypanosoma brucei parasites in sub-Saharan Africa and American trypanosomiasis, or Chagas disease, is caused by Trypanosoma cruzi parasites in Latin America and is transmitted by the triatomine or ‘kissing’ bug.Download the sample report @ https://www.pharmaproff.com/request-sample/1075
The signs and symptoms observed in patients with trypanosomiasis are swollen lymph glands, blood in urine, fever, aching muscles and joints. Tsetse fly is the main vector for Trypanosoma. People in sub-Saharan African countries are mostly exposed to tsetse fly.
Get the detailed analysis @ https://www.pharmaproff.com/report/trypanosomiasis-therapeutics-pipeline-analysis
Some of the complications associated with trypanosomiasis are wasting syndrome, aspiration pneumonia, anemia, meningoencephalitis, and seizures. Sequella Inc. is in the process of developing SQ109 as a cell wall inhibitor for the treatment of trypanosomiasis.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1075
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Trypanosomiasis Therapeutics Pipeline Analysis 2018 | Sequella, Inc. here
News-ID: 1759087 • Views: …
More Releases for Trypanosoma
Chagas Disease Market Growth, Trends & Forecast 2025 | Top Key players - Bayer A …
Chagas Disease Market, as analyzed in the study by DataM Intelligence, presents a detailed overview of the industry with in-depth insights, historical data, and key statistics. The report thoroughly examines market dynamics, competitive strategies, and major players, highlighting their product lines, pricing structures, financials, growth plans, and regional outreach.
The Global Chagas Disease Market reached US$ 268 million in 2023 and is expected to reach US$ 467 million by 2031, growing…
Sleeping Sickness Testing Market to be innovatively servile
The Sleeping Sickness Testing Market is expected to witness an escalation going forward. With health apps, biosensors, AI, VR, telehealth, robots, cloud computing, predictive analysis, and EHRs being rampantly used, there is nothing to hold the healthcare vertical from soaring high. The healthcare vertical, would, see its cash registers ringing on the count of digital IoT creeping in at a rapid pace.
Sleeping Sickness is the most common life-threatening infection encountered…
Chagas Disease Market Comprehensive Analysis Growth By Leading Players Nortec Qu …
For instance, in 2017, the U.S. Food and Drug Administration (FDA) granted approval to Chemo Group for its drug benznidazole indicated for the treatment of Chagas disease in patients aged 2–12 years. Currently, according to data published by Centers of Disease Control and Prevention (CDC), in 2013, over 300,000 people are suffering from Trypanosoma cruzi infection in the U.S. Hence, approval of Chagas disease treatment drugs in such key regions…
Chagas Disease Treatment Market Revenue Opportunies By Key Vendors Nortec Quimic …
Chagas Disease Treatment Market is expected to have a highly positive outlook for the next five years 2018–2026 according to a recently released Chagas Disease Treatment Market research report. The major takeaways in the report are product segment analysis, application segment analysis, regional segment analysis and data of the major Chagas Disease Treatment Market players from around the world. The report presents an introductory as well as detailed information about…
Chagas Disease Treatment Market to Surpass US$ 10.29 Mn Threshold by 2025
Chagas disease is a tropical parasitic disease and is endemic in 21 countries in Latin America. Chagas disease can transmitted through blood transfusion, organ transplantation, as well as congenital and oral transmissions. Chagas disease is endemic to Latin America, however, in the recent past, there is a rise in global incidence of Chagas disease due to the migration of Latin American people to other countries. According to data published by…
Chagas Disease Treatment Market Global Industry Insights, and Forecast till 2025
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,…
